Vivos Therapeutics, Inc. (NASDAQ:VVOS) Given Consensus Recommendation of “Hold” by Brokerages

Vivos Therapeutics, Inc. (NASDAQ:VVOS) has been assigned an average recommendation of “Hold” from the five ratings firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $4.9167.

A number of research analysts have recently weighed in on the company. Zacks Research raised Vivos Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, December 1st. Ascendiant Capital Markets decreased their target price on shares of Vivos Therapeutics from $6.50 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, December 3rd. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research report on Wednesday, October 8th. Finally, HC Wainwright began coverage on shares of Vivos Therapeutics in a research report on Monday, November 17th. They set a “buy” rating and a $7.00 price objective on the stock.

Institutional Trading of Vivos Therapeutics

A number of large investors have recently made changes to their positions in VVOS. Connective Capital Management LLC purchased a new position in Vivos Therapeutics during the third quarter worth $620,000. B. Riley Wealth Advisors Inc. acquired a new stake in Vivos Therapeutics in the second quarter worth about $220,000. Finally, XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics in the 2nd quarter valued at $65,000. 26.35% of the stock is currently owned by institutional investors.

Vivos Therapeutics Trading Down 7.2%

NASDAQ VVOS opened at $2.06 on Tuesday. Vivos Therapeutics has a twelve month low of $1.92 and a twelve month high of $7.95. The stock’s 50 day moving average is $2.21 and its 200 day moving average is $3.43. The firm has a market capitalization of $18.52 million, a PE ratio of -1.16 and a beta of 6.89. The company has a quick ratio of 0.78, a current ratio of 0.78 and a debt-to-equity ratio of 3.31.

Vivos Therapeutics (NASDAQ:VVOS) last released its quarterly earnings data on Wednesday, November 19th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.53) by $0.04. The business had revenue of $6.78 million for the quarter, compared to analysts’ expectations of $4.49 million. Vivos Therapeutics had a negative return on equity of 351.28% and a negative net margin of 98.77%. Research analysts forecast that Vivos Therapeutics will post -1.79 earnings per share for the current fiscal year.

About Vivos Therapeutics

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.